People News: Alexion Pharmaceuticals and KV Pharmaceutical
Specialty firm KV Pharmaceutical named David Van Vliet CEO, with a term through December 31, 2011. Van Vliet has served as interim president and CEO since December 2008.
There's a reason pharma lags on the programmatic adoption curve: It's a heavily regulated industry, and there are concerns around privacy.
Where are the discussions about applying proven behavior change models or the principles of adult learning and health literacy?
Such intense interest in health content is a rich opportunity to engage, inform, support, and motivate key customer constituencies.